简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
04
2024-09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
28
2024-08
Articles of Association
27
2024-08
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
23
2024-08
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
14
2024-08
Notice of Board Meeting
07
2024-08
Next Day Disclosure Return
07
2024-08
Completion of Placing of New Shares under General Mandate
05
2024-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
05
2024-08
Approval Obtained for Initiating Clinical Trials for Dulaglutide Injection (BA5101) in the U.S.
31
2024-07
Placing of New Shares under General Mandate
1
2
3
4
5
Follow me
鲁公网安备37069102000284